Skip to main navigation Skip to search Skip to main content

Accepting PhD Students

PhD projects

Cellular immunotherapy

20102026

Research activity per year

Personal profile

Research interests

Cellular immunotherapy, chimeric-antigen-receptor-modified T cells

Gene therapy and stem cell biology in thalassemia and other diseases

Pediatric oncology and hematopoietic stem cell transplantation

Intellectual Property

Histone deacetylase (HDAC) inhibitor up-regulates CAR expression and targeted antigen intensity, increasing antitumor efficacy, Patent No. US 11,547,740 B2 (10 Jan 2023) & US 10,279,009 B2 (7 May 2019)

A chimeric antigen receptor of T cells specific to CD19 antigen for the treatment of patients with B-cell hematologic malignancies by using cellular therapy, TH2001002539 (8 May 2020)

A chimeric antigen receptor of T cells and modified cell carrying the receptor, PCT/TH2021/000018 (5 May 2021) WO 2021/225532 A1 (11 Nov 2021) 

CD19-specific chimeric antigen receptor comprising a CD28/CD40 co-stimulatory domain, PCT/TH2025/050002 WO 2025/170547 (5 Feb 2025)

CD3/GD2 bispecifc T cell engager, TH2503000232 (26 Feb 2025)

A chimeric antigen receptor of T cells specific to GD2 protein-expressing cells, TH2203000624 (9 Mar 2022)

A short version of chimeric antigen receptor of T cells activating function of T lymphocyte, TH2101000475 (27 Jan 2021)

Education/Academic qualification

Bachelor, Doctor of Medicine, Faculty of Medicine Ramathibodi Hospital

Award Date: 7 Mar 2000

Fingerprint

Dive into the research topics where Usanarat Anurathapan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or